Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
11:07am, Wednesday, 30'th Apr 2025
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort
08:00am, Tuesday, 29'th Apr 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--The Charles River Incubator Program announces its first cohort, expediting the development of technologies and life-changing therapies for patie
Here's How Charles River is Placed Just Ahead of Q1 Earnings
10:15am, Monday, 28'th Apr 2025
CRL's first-quarter 2025 performance is expected to have been hurt by a challenging biopharmaceutical environment.
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
08:00am, Tuesday, 22'nd Apr 2025
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology dr
Aldeyra Therapeutics: A Mispriced Gem With Reproxalap's CRL Creating A Golden Buying Opportunity
10:52am, Monday, 21'st Apr 2025
Aldeyra Therapeutics' stock offers a compelling contrarian opportunity, rebounding 70% after a 75% drop due to an FDA CRL for Reproxalap in dry eye disease. The FDA requested additional efficacy data.
The 2 Worst Performing S&P 500 Stocks YTD: Buy, Sell, or Avoid?
07:56am, Wednesday, 16'th Apr 2025
It's been a turbulent start to 2025 for investors. The market has faced a wave of selling pressure driven by surging tariffs, escalating geopolitical tensions, and growing fears of a global economic s
Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call
04:30pm, Tuesday, 15'th Apr 2025
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules first-quarter 2025 earnings release and conference call.
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?
09:30am, Tuesday, 15'th Apr 2025
Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increas
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
10:44am, Friday, 11'th Apr 2025
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
01:15pm, Thursday, 10'th Apr 2025
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
After A CRL Setback, Aldeyra Therapeutics Is A Compelling Speculative Buy
04:51am, Tuesday, 08'th Apr 2025
Aldeyra Therapeutics' stock plummeted 74% due to an FDA Complete Response Letter for reproxalap but presents a favorable risk-reward for speculative investors. Despite past setbacks, ALDX's history of
Charles River & Valo Health's Logica Identifies New Lupus Drug Candidate
10:20am, Monday, 31'st Mar 2025
Charles River and Valo Health identify a potential therapeutic for lupus using their combined offering, Logica.
Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform
08:00am, Tuesday, 25'th Mar 2025
WILMINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Valo Health announce the identification of an advanceable product candidate for treatment of lupus and othe
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
12:36pm, Friday, 21'st Mar 2025
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility
04:05am, Tuesday, 04'th Mar 2025
PORTO, Portugal & SAN FRANCISCO--(BUSINESS WIRE)--FairJourney Biologics S.A., leaders in the discovery and optimization of antibodies, today announced that it had completed the acquisition of the Sout
